FeesSafety
Pluang+

Ideaya Biosciences advances cancer treatments with darovasertib NDA and IDE849 trials, backed by strong funding.

Analyst Insights
17 Nov 2026, 21:56 WIB
Seeking Alpha
View Source
Bullish
Ideaya Biosciences advances cancer treatments with darovasertib NDA and IDE849 trials, backed by strong funding.

Ideaya Biosciences has completed the NDA submission for darovasertib, a drug targeting metastatic uveal melanoma, and is progressing IDE849 with multiple planned registrational studies. Darovasertib combined with crizotinib is being tested in a phase 3 trial for adjuvant treatment of this cancer. With $1.15 billion in cash and securities, Ideaya is well-funded through 2030, minimizing near-term dilution risks. These developments position Ideaya as a promising biotech investment with ongoing clinical advancements and regulatory opportunities.

Ideaya Biosciences stands on a strong financial footing with $1.15 billion in cash and securities as of November 18, 2026. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 18, 2026 00:21 WIB: out of 150 priced US health-sector stocks tradable on Pluang, 41 rose and 107 fell. Notable movers include HIMS at USD 17.57 with a 1-day change of -5.33% and Pluang order activity showing 67% Sell / 33% Buy, MESO at USD 11.86 down 4.74%, and SYRE at USD 94.95 down 4.45%.

More News

Texas Tech launches $24M weather system expansion in Texas Hill Country to boost severe weather forecasting.

Texas Tech launches $24M weather system expansion in Texas Hill Country to boost severe weather forecasting.

Texas Tech University is expanding its weather monitoring and forecasting infrastructure into the Texas Hill Country with a $24 million state investment and support from Dell Technologies. The project includes 40 new weather stations, three advanced ...

Market News
Neutral
1 hour ago
Bipartisan bills aim to stop forced arbitration in child harm cases on online gaming platforms like Roblox

Bipartisan bills aim to stop forced arbitration in child harm cases on online gaming platforms like Roblox

Two bipartisan bills introduced in the U.S. Senate seek to prevent technology companies from using forced arbitration to block families from suing over child sexual exploitation and other harms on platforms like Roblox. These laws would allow familie...

Market News
Bearish
2 hours ago
Guidepoint launches MCP to integrate expert research directly into AI platforms for seamless workflows

Guidepoint launches MCP to integrate expert research directly into AI platforms for seamless workflows

Guidepoint has introduced Guidepoint MCP, a new tool that integrates its extensive expert research library and advisor network directly into popular AI platforms like ChatGPT and Claude. This innovation allows research teams to conduct full primary r...

Others
Bullish
2 hours ago
Amplify ETFs wins 2026 awards for best crypto-linked and options strategies ETFs.

Amplify ETFs wins 2026 awards for best crypto-linked and options strategies ETFs.

Amplify ETFs has been recognized at the 2026 ETF Express U.S. ETF Awards, winning Best Crypto-Linked ETF Issuer ($1 billion+) and Best Options Strategies ETF Issuer ($1 billion-$10 billion). This marks their second consecutive win for crypto-linked E...

Bullish
2 hours ago
Ipsos repurchased over 80,000 shares from Nov 9-13, 2026, at average prices around €36 each.

Ipsos repurchased over 80,000 shares from Nov 9-13, 2026, at average prices around €36 each.

Between November 9 and 13, 2026, Ipsos conducted a share buyback program, repurchasing a total of more than 80,000 ordinary shares across different markets. The average purchase price per share ranged around €36. This move reflects Ipsos's strategy t...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App